Modulation of Glioma Growth and Invasion by HCMV Glycoprotein B
HCMV 糖蛋白 B 对神经胶质瘤生长和侵袭的调节
基本信息
- 批准号:7935186
- 负责人:
- 金额:$ 20.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-20 至 2012-12-31
- 项目状态:已结题
- 来源:
- 关键词:AdultAntiviral AgentsBindingBiological AssayBiologyBlocking AntibodiesBlood VesselsBrainCMV glycoprotein BCell Cycle CheckpointCell ProliferationCell SurvivalCell surfaceCellsCephalicChronicClinicalCytomegalovirusCytomegalovirus InfectionsDataEctopic ExpressionEndothelial CellsEngineeringEtiologyExcisionExhibitsGene ExpressionGlioblastomaGliomaGliomagenesisGlycoproteinsGrowthHumanHuman VirusIn VitroInfectionIntegrinsLaboratoriesLeadLesionLigandsMalignant - descriptorMalignant GliomaMalignant NeoplasmsMeasuresMigration AssayModelingNon-MalignantNucleic AcidsOncogenicOperative Surgical ProceduresPDGFRB genePTK2 geneParacrine CommunicationPathogenesisPathologyPathway interactionsPatientsPhenotypePlatelet-Derived Growth FactorPlatelet-Derived Growth Factor ReceptorPlatelet-Derived Growth Factor alpha ReceptorPlayPopulationPrimary Brain NeoplasmsProtein Tyrosine KinaseProteinsPublishingReceptor ActivationReceptor Protein-Tyrosine KinasesRecombinantsReportingRoleSignal PathwaySignal TransductionSliceStagingStaining methodStainsSurfaceTP53 geneTestingTumor AngiogenesisTumor Suppressor ProteinsTumor VolumeTyrosineViralViral Envelope ProteinsXenograft procedureangiogenesisautocrinebasebrain tissuecell growthcell motilitydensityglioma cell linein vivomalignant phenotypemigrationneoplastic cellneural precursor cellneutralizing antibodynovel therapeutic interventionoverexpressionpublic health relevanceresearch studyresponsetumortumor growth
项目摘要
DESCRIPTION (provided by applicant): Glioblastoma (GBM) is the most common primary brain tumor in adults and is uniformly fatal. Our laboratory was the first to show that human cytomegalovirus (HCMV) nucleic acids and proteins are present in over 90% of human malignant gliomas, and these findings have now been confirmed by three independent groups. Recent studies have shown that HCMV infection levels negatively correlate with patient survival, suggesting that HCMV may induce a shift towards a more aggressive and invasive glioma phenotype. We recently published two reports demonstrating that HCMV infection and gene expression in GBM cells can induce cellular tyrosine kinase signaling pathways critical for tumor growth (Akt, PLC3, FAK), inhibit p53 and Rb tumor suppressor activity, alter cell cycle checkpoint controls, and promote cell proliferation. We have also discovered that HCMV activates robust PDGFR1 signaling in GBM cells, and that PDGFR1 activation is actually required for HCMV infection. This finding is particularly relevant to glioma biology since PDGFR1 is amplified/overexpressed in a high percentage of GBM cells and activation of PDGFR1 in normal NPCs is implicated in the earliest stages of gliomagenesis. Our published and preliminary data indicate that HCMV glycoprotein B (gB, the most abundant viral envelope protein) is the viral moiety that binds and Tyrosine phosphorylates PDGFR1 and activates downstream PI3K-Akt signaling in glioma cells. Most recently, we have evidence that gB induces haptotactic glioma cell migration and that HCMV-induced glioma transwell migration is inhibited both by PDGFR1 blocking antibodies or gB neutralizing antibodies. Taken together, our data suggest that the interaction between HCMV gB and PDGFR1 expressed on the surface of glioma cells may play a critical role in modulating glioma growth and invasion. To investigate these hypotheses, we propose to use in vitro, ex vivo, and in vivo assays which will test whether HCMV-infected and gB -expressing human glioma cells exhibit enhanced growth and invasiveness. Our laboratory has unique access to human primary glioblastoma-derived cultures which endogenously express several HCMV gene products, including gB. We plan to use these primary glioma cultures, super-infected with a clinical HCMV isolate and engineered to ectopically express gB for transwell migration, brain slice invasion, and in vivo tumor growth assays. If we find that HCMV and gB do promote glioma growth and invasiveness, we plan to investigate specific mechanisms underlying this modulation, including cell proliferation, cell invasion, and tumor angiogenesis. Results from these experiments will be critical in understanding the role that HCMV plays in the pathogenesis of human gliomas and may uncover novel therapeutic approaches against this incurable human cancer, based on antiviral strategies.
PUBLIC HEALTH RELEVANCE: Our laboratory has found that a common human virus, cytomegalovirus (HCMV) is present in over 90% of malignant gliomas, a uniformly fatal, highly aggressive cancer, with no known etiology or treatment. This proposal will investigate the role of HCMV envelope glycoprotein B in promoting glioma growth and invasion. Results from experiments proposed herein may lead to novel therapeutic approaches based on antiviral treatments for glioma patients.
描述(申请人提供):胶质母细胞瘤(GBM)是成人最常见的原发脑肿瘤,通常是致命的。本实验室首次证实人类巨细胞病毒(HCMV)核酸和蛋白质存在于90%以上的人类恶性胶质瘤中,这一发现现已被三个独立的研究小组证实。最近的研究表明,HCMV感染水平与患者生存期呈负相关,提示HCMV可能诱导向更具侵袭性和侵袭性的胶质瘤表型转变。我们最近发表了两篇报道,证明在GBM细胞中,HCMV感染和基因表达可以诱导肿瘤生长关键的细胞酪氨酸激酶信号通路(Akt、PLC3、FAK),抑制P53和Rb肿瘤抑制活性,改变细胞周期检查点控制,促进细胞增殖。我们还发现,HCMV激活了GBM细胞中强大的PDGFR1信号,而PDGFR1的激活实际上是HCMV感染所必需的。这一发现与胶质瘤生物学特别相关,因为PDGFR1在高比例的GBM细胞中被扩增/过表达,而在正常的NPC中,PDGFR1的激活与胶质瘤形成的早期阶段有关。我们已发表的和初步的数据表明,HCMV糖蛋白B(GB,最丰富的病毒包膜蛋白)是胶质瘤细胞中结合和酪氨酸磷酸化PDGFR1并激活下游PI3K-Akt信号的病毒部分。最近,我们有证据表明,GB诱导胶质瘤细胞向肝细胞迁移,并且HCMV诱导的胶质瘤跨壁迁移被PDGFR1阻断抗体或GB中和抗体抑制。综上所述,我们的数据提示,表达在胶质瘤细胞表面的HCMV-GB和PDGFR1之间的相互作用可能在调节胶质瘤的生长和侵袭中发挥关键作用。为了研究这些假说,我们建议使用体外、体外和体内试验,以测试HCMV感染和表达GB的人脑胶质瘤细胞是否表现出增强的生长和侵袭力。我们的实验室有独特的途径获得人类原代胶质母细胞瘤来源的培养物,这些培养物内源性表达几种HCMV基因产物,包括GB。我们计划使用这些原代胶质瘤培养物,超级感染临床HCMV分离株,并设计成异位表达GB,用于跨井迁移、脑片侵袭和体内肿瘤生长分析。如果我们发现HCMV和GB确实促进了胶质瘤的生长和侵袭性,我们计划研究这种调节的特定机制,包括细胞增殖、细胞侵袭和肿瘤血管生成。这些实验的结果将是理解巨细胞病毒在人类胶质瘤发病机制中所起作用的关键,并可能揭示基于抗病毒策略的针对这种无法治愈的人类癌症的新的治疗方法。
公共卫生相关性:我们的实验室发现一种常见的人类病毒,巨细胞病毒(HCMV)存在于90%以上的恶性胶质瘤中,这是一种普遍致命的高度侵袭性癌症,目前尚不清楚病因或治疗方法。本研究将探讨人巨细胞病毒包膜糖蛋白B在促进胶质瘤生长和侵袭中的作用。本文提出的实验结果可能导致基于抗病毒治疗的胶质瘤患者的新的治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Liliana Soroceanu其他文献
Liliana Soroceanu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Liliana Soroceanu', 18)}}的其他基金
Cytomegalovirus Gene Expression and Strain Variability in Glioma Pathogenesis
胶质瘤发病机制中的巨细胞病毒基因表达和株变异
- 批准号:
8415941 - 财政年份:2010
- 资助金额:
$ 20.88万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 20.88万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 20.88万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 20.88万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 20.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 20.88万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 20.88万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 20.88万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 20.88万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 20.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 20.88万 - 项目类别: